TY - JOUR
T1 - Assessing the Pathophysiology of Hyperglycemia in the D iabetes RE lated to A cute Pancreatitis and Its M echanisms Study
T2 - From the Type 1 Diabetes in Acute Pancreatitis Consortium
AU - Type 1 Diabetes in Acute Pancreatitis Consortium (T1DAPC)
AU - Dungan, Kathleen M.
AU - Hart, Phil A.
AU - Andersen, Dana K.
AU - Basina, Marina
AU - Chinchilli, Vernon M.
AU - Danielson, Kirstie K.
AU - Evans-Molina, Carmella
AU - Goodarzi, Mark O.
AU - Greenbaum, Carla J.
AU - Kalyani, Rita R.
AU - Laughlin, Maren R.
AU - Pichardo-Lowden, Ariana
AU - Pratley, Richard E.
AU - Serrano, Jose
AU - Sims, Emily K.
AU - Speake, Cate
AU - Yadav, Dhiraj
AU - Bellin, Melena D.
AU - Toledo, Frederico G.S.
N1 - Publisher Copyright:
© Wolters Kluwer Health, Inc. All rights reserved.
PY - 2022/7/1
Y1 - 2022/7/1
N2 - Objectives The metabolic abnormalities that lead to diabetes mellitus (DM) after an episode of acute pancreatitis (AP) have not been extensively studied. This article describes the objectives, hypotheses, and methods of mechanistic studies of glucose metabolism that comprise secondary outcomes of the DREAM (Diabetes RElated to Acute pancreatitis and its Mechanisms) Study. Methods Three months after an index episode of AP, participants without preexisting DM will undergo baseline testing with an oral glucose tolerance test. Participants will be followed longitudinally in three subcohorts with distinct metabolic tests. In the first and largest subcohort, oral glucose tolerance tests will be repeated 12 months after AP and annually to assess changes in β-cell function, insulin secretion, and insulin sensitivity. In the second, mixed meal tolerance tests will be performed at 3 and 12 months, then annually, and following incident DM to assess incretin and pancreatic polypeptide responses. In the third, frequently sampled intravenous glucose tolerance tests will be performed at 3 months and 12 months to assess the first-phase insulin response and more precisely measure β-cell function and insulin sensitivity. Conclusions The DREAM study will comprehensively assess the metabolic and endocrine changes that precede and lead to the development of DM after AP.
AB - Objectives The metabolic abnormalities that lead to diabetes mellitus (DM) after an episode of acute pancreatitis (AP) have not been extensively studied. This article describes the objectives, hypotheses, and methods of mechanistic studies of glucose metabolism that comprise secondary outcomes of the DREAM (Diabetes RElated to Acute pancreatitis and its Mechanisms) Study. Methods Three months after an index episode of AP, participants without preexisting DM will undergo baseline testing with an oral glucose tolerance test. Participants will be followed longitudinally in three subcohorts with distinct metabolic tests. In the first and largest subcohort, oral glucose tolerance tests will be repeated 12 months after AP and annually to assess changes in β-cell function, insulin secretion, and insulin sensitivity. In the second, mixed meal tolerance tests will be performed at 3 and 12 months, then annually, and following incident DM to assess incretin and pancreatic polypeptide responses. In the third, frequently sampled intravenous glucose tolerance tests will be performed at 3 months and 12 months to assess the first-phase insulin response and more precisely measure β-cell function and insulin sensitivity. Conclusions The DREAM study will comprehensively assess the metabolic and endocrine changes that precede and lead to the development of DM after AP.
UR - http://www.scopus.com/inward/record.url?scp=85139571728&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85139571728&partnerID=8YFLogxK
U2 - 10.1097/MPA.0000000000002074
DO - 10.1097/MPA.0000000000002074
M3 - Article
C2 - 36206461
AN - SCOPUS:85139571728
SN - 0885-3177
VL - 51
SP - 575
EP - 579
JO - Pancreas
JF - Pancreas
IS - 6
ER -